| 前收市價 | 15.70 |
| 開市 | 15.70 |
| 買盤 | 15.80 x 無 |
| 賣出價 | 16.10 x 無 |
| 今日波幅 | 15.70 - 15.80 |
| 52 週波幅 | 13.12 - 21.85 |
| 成交量 | |
| 平均成交量 | 0 |
| 市值 | 無 |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | 無 |
| 業績公佈日 | 2024年7月25日 - 2024年7月29日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
ZacksIndivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates
Indivior (INDV) delivered earnings and revenue surprises of -2.63% and 5.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Reuters
UPDATE 1-UK-listed drugmaker Indivior seeks shareholder nod for US listing
UK-listed drugmaker Indivior plans to seek shareholder approval next month for a primary listing in the United States, the company said on Thursday, which would add it to a growing list of firms leaving the London stock market. Indivior had, in February, announced its intent to shift its listing by the middle of the year to the U.S., which, it argued, reflected its growth opportunities as its proprietary treatments are U.S.-centred and U.S.-based investors account for nearly 50% of its overall shareholder base. The list of UK-based companies that have already listed in the United States includes ARM, the UK's biggest chip company, as well as building supplies firm CRH and plumbing equipment company Ferguson.
ZacksIndivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?
Indivior (INDV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
